reconstituting ghk cu 100mg GHK-Cu-100 mg GHK-CU ( 100mg ) |

Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono

It's aggregated anecdote, not evidence

Liquid is pre-prepared for research convenience

Research on Phase II detoxification estimates that glutathione conjugation is responsible for detoxifying up to 60% of all therapeutic drugs, environmental toxins, and heavy metals

[DOI] [PMC free article] [PubMed] [Google Scholar] 111.Kumar P., Liu C., Hsu J.W., Chacko S., Minard C.G., Jahoor F., Sekhar R.V

It's metabolized and cleared by the kidneys, and while preclinical data shows promise for kidney recovery, comprehensive human safety isn't established